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http://dx.doi.org/10.1016/j.ejvs.2014.06.044Part Two: Against the Motion. Venous Perforator Surgery is Unproven and
Does not Reduce Recurrences
Thomas F. O’Donnell, Jr., M.D.
The Cardiovascular Center, Tufts Medical Center, Boston, MA, USAThis author’s position in this debate is that treatment of
incompetent perforating veins (IPVs) in association with
ablation of the great saphenous vein (GSV) for axial reﬂux
does not reduce the recurrence of varicose veins (REVAS).
The argument to not treat perforating veins peremptorily at
the time of GSV surgery, as a method to prevent recurrence
following GSV surgery, is based on the following:
1. IPVs are not the major cause of REVAS
2. The treatment of GSV reﬂux alone will concomitantly
correct a signiﬁcant proportion of IPVs3. The interruption of IPVs with many techniques is
associated with residual or “missed” IPVs, and this
procedure is not permanent or durable, leading to true
REVAS of the IPVs
4. Recurrence is frequently related to progression of
chronic venous insufﬁciency, which is not prevented
by pre-emptory IPV ablation at the time of GSV ablation.
OVERVIEW
Perrin et al. led a consensus conference in 1998, which
brought both deﬁnition and classiﬁcation to the problem
European Journal of Vascular and Endovascular Surgery Volume 48 Issue 3 p. 239e247 September/2014 243of REVAS1dmuch like the CEAP classiﬁcation did for the
larger area of chronic venous insufﬁciency.2 REVAS was
deﬁned as “the existence of varicose veins in a lower limb
previously operated on for varicose veins with or without
adjuvant therapies”, and was classiﬁed by: (1) topograph-
ical sites, such as the thigh; (2) source of recurrence, the
cause of deep venous reﬂux into the superﬁcial system,
such as the perforators-thigh or calf; and (3) the nature of
the sources, whether the recurrence was at the site of
previous surgery or at another new site. REVAS is
customarily divided into anatomical recurrence, which is
deﬁned by duplex ultrasound and may be asymptomatic;
and clinical recurrence, which is associated with symp-
tomatic recurrent varicosities. Finally, whether the patient
underwent treatment of REVAS can be viewed as a patient
outcome measure.IPVS ARE NOT THE MAJOR CAUSE OF REVAS
Over the last decade, endovenous ablation (EVA) of the
GSV or small saphenous veins (SSV) by laser (EVLA) or
radiofrequency (RFA) has become the principle therapy for
varicose veins in the USA rather than ligation and stripping
(L&S); as a result, EVA has increased 450-fold over the last
decade.3 EVA has been recommended as the primary
procedure for saphenous incompetence by the Society for
Vascular Surgery/American Venous Forum guidelines for
varicose veins,4 and the UK’s National Institute for Health
and Care Excellence guidelines.5 Thus, REVAS associated
with EVA becomes an important consideration. L&S of the
GSV by the short strip technique usually avoids treatment
of the below-knee GSV,6 while EVA may access the below-
knee GSV and ablate the upper portion of the below-knee
GSV.3 REVAS has been well studied following L&S. In a
multicenter study from eight countries involving 199 pa-
tients with REVAS following L&S, Perrin et al. showed that
the commonest sites of recurrence were the thigh (68%)
and the lower leg (85%).7 By contrast, in that study the
sapheno-femoral region (47%) and thigh perforators (30%)
were the major sources of REVAS. The lower leg IPVs were
the source of recurrence in 43% of limbs. Unfortunately,
no information was given about the number of limbs that
had speciﬁc treatment of IPVs at the time of their initial
L&S.
Employing the REVAS classiﬁcation system, Bush et al.
reported on REVAS from seven centers treating 2380 pa-
tients, of which a strikingly low 164 (7%) developed REVAS
at a median of 3 years.8 Laser ablation was performed as
the initial procedure in 80% of patients, while the older RFA
catheter was used in the majority of the RFA procedures.
No information is provided on whether IPVs were treatedTable 1. The effect of great saphenous vein treatment by ligation and
Reference Limbs (n) Examination time (weeks) Preope
Stuart et al.12 2 14 40 (65)
Mendes et al.13 24 12 24 (100
Blomgren et al.14 103 8 42 (100
Gohel et al.15 115 e 59 (52)with the original ablation. The authors use the all-
encompassing term of “perforators” for the source of
reﬂux. When the speciﬁc anatomical site is deﬁned, perfo-
rators in the thigh rather than the calf were the site asso-
ciated with a statistical increase in GSV recanalization. In
their analysis, REVAS appears to be deﬁned as reﬂux on
duplex and the incidence of clinical REVAS is difﬁcult to
tease out. Of interest to this debate, REVAS developed at
new, previously nonreﬂuxing sitesd16% at the SSV and 24%
at the AAGSV. Thus, a total of 40% of all REVAS was due to
disease progression and not amenable to pre-emptory
treatment of the IPVs at the time of EVA.
The least biased information and of highest evidentiary
value about REVAS following EVA can be derived from
randomized controlled trials (RCTs), where the data is
collected prospectively through a uniform protocol,
particularly with duplex ultrasound follow-up and prefer-
ably using the REVAS classiﬁcation.3 Those RCTs in which no
speciﬁc treatment was provided to the IPVs were exam-
ined. In an earlier and smaller RCT, Perala et al. described
their ﬁndings at 3 years following RFA in 15 patients.9 The
cause of REVAS, which occurred in 33% of the patients,
were reﬂux in an anterior accessory saphenous vein (AASV),
a patent duplicate GSV, but no IPVs were detected. Ras-
mussen et al. compared EVLA (67 limbs/60 patients) with
L&S (67 limbs in 58 patients) in a RCT over a 5-year
period.10 The patients in this RCT had their varicosities
treated with stab phlebectomies for EVA and L&S, but no
speciﬁc treatment was directed at IPVs. At 5 years, there
was no difference in clinical REVAS between EVLA (47%)
and L&S (55%), but retreatment, principally by sclerother-
apy, was required in a lesser proportion (39%). Reﬂux was
found in the AASV in 24% of the limbs and in the thigh
perforators in another 20%, but calf IPVs accounted for only
16%. Disselhoff et al. compared EVLA with L&S in 120 pa-
tients; at 2 years, calf ICPVs were not described as a cause
of REVAS.11THE TREATMENT OF GSV REFLUX ALONE CAN CORRECT A
GREAT PROPORTION OF IPVS
Stuart et al. were one of the ﬁrst groups to demonstrate a
reduction in the number of duplex-detected IPVs after L&S
of the GSV from 65% of limbs preoperatively to 37% post-
operatively (p < .01), while the proportion of IPVs declined
from 52% to 28%.12 However, they found that deep venous
incompetence adversely affected the reduction in IPVs with
L&S. Table 1 shows a similar signiﬁcant decrease in the
proportion of limbs with IPVs following L&S in several other
series of predominantly CEAP C2/3 patients.13,14 In a duplex
follow-up of the ESCHAR RCT by Gohel et al., in which allstripping on incompetent perforating veins (IPVs).
rative IPVs, n (%) Postoperative IPVs, n (%) New IPVs, n (%)
23 (37) e
) 8 (33) e
) 23 (45) 8 (18)
44 (43) 12 (12)
244 Trans-Atlantic Debatepatients were C5/6 and many had deep venous incompe-
tence, there was a smaller, but signiﬁcant, decrease in
postoperative IPVs.15 In these combined series, the average
decrease in of IPVs following treatment of the GSV post-
operatively was 50%.TREATMENT OF IPVS BY ABLATION WITH PAST AND
CURRENT TECHNIQUES IS HAMPERED BY RESIDUAL OR
MISSED IPVS, WHILE THE TREATMENT OF IPVS IS NOT
PERMANENT OR DURABLE LEADING TO TRUE REVAS OF
ICPVS
To advocate a procedure that is “preventative” the tech-
nique must have a high initial success rate, and the pro-
cedure must be effective long enough to garner the
proposed late beneﬁts against REVAS. The current treat-
ment of IPVs has evolved from the open procedures of
Linton and Cockett,16,17 where all perforating veins were
visualized and ligated via a long medial subfascial incision,
through subfascial endoscopic perforating vein surgery
(SEPS), where the IPVs were selectively ablated by an
endoscopic approach,18,19 to the current technique of direct
percutaneous thermal or sclerotherapy treatment of the
IPVs under ultrasound guidance.20 The experience of this
author has shown an early ultrasound residual or “missed
IPV” rate of 22% in 19 limbs following SEPS,21 which is
similar to the residual rate described by Sybrandy et al.
(20%) in a 40-patient RCT, which compared SEPS with theTable 2. A comparison of the occlusion/residual rate with direct percu
veins following subfascial endoscopic perforating vein surgery (SEPS).
Reference Limbs (n)
RFA
Chang et al.26
Lumsden et al.27 55
Elias and Peden29 e
van den Bos et al.28 12
Bacon et al.36 58
Hingorani et al.30 38
Lawrence et al.34 51
Laser
Proebstle and Herdemann31 60
Kabnick32 e
Elias and Peden29 e
Murphy33 e
Sclerotherapy
Masuda et al.38 80
Kiguchi et al.37 62
SEPS
Iafrati et al.21 15
Roka et al.25 92
Sybrandy et al.22 (SEPS) 20
Sybrandy et al.22 (Linton) 19
Note. RFA ¼ radiofrequency ablation.
* Data represents % residual IPVs rather than occluded IPVs.Linton procedure (0% residual rate).22 On follow-up duplex
examination, the large 200-limb Dutch SEPS RCT revealed at
least one residual/missed IPV in 50% of the procedures.23
As the former trial suggests, SEPS is highly operator
dependent and this is underscored by Kolvenbach’s “redo
SEPS” series of 19 patients, which was principally referral-
based, presumably from lower volume centers.24 Besides
technical problems with residual IPVs, progression of a
perforator, which was normal on initial duplex assessment,
to an IPV frequently occurs. In the REVAS classiﬁcation, this
has been deﬁned as new REVAS. Sybrandy et al. observed
that the initial 0% residual IPV rate with the Linton proce-
dure had climbed to a 45% new REVAS in later follow-up,
while following SEPS this ﬁgure had doubled to a 42%
new REVAS rate.22 After SEPS in 92 limbs, no residual IPVs
were observed on duplex in Roka’s series, but new REVAS of
IPVs developed in 20 limbs (20%) over a mean follow-up of
3.7 years.25
The current technique of thermal ablation of IPVs
(transluminal occlusion of perforator technique [TRLOP] or
perforator ablation procedure [PAPS]) is hampered by
considerable operator variability, with a steep learning
curve.20 Table 2 summarizes the incidence of residual IPVs
after PAPS in the published literature, as well as from series
presented at meetings. Following RFAePAPS, the rate of
early IPV occlusion varies from two series in the 60% (40%
residual REVAS rate) to several at 90% or above.26e30
LASERePAPS appeared to have somewhat better earlytaneous ablation of perforators to residual incompetent perforator
Perforators (n) Follow-up (mo) Occluded/residual (%)
38 6 63/37
97 12 44/56
20 0.75 81/19
14 0.25 100/0
125 60 66/34
48 1 88/12
86 e 58/42 (2 y 79/29)
67 3 99/1
25 4 85/15
50 e 90/10
100 e 90/10
e e 98/2 (20 mo, 75%)
189 36 54/46
18 5.5 22*
e 0.25 100*
e 1.5 28*
e e 0*
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is best appreciated from the large experience of Lawrence
et al.,34 where the initial success rate with RFAePAPS was
58% and rose to 79% after 2 years of experience. Strong
further evidence on the lack of permanence of IPV treat-
ment (true REVAS) is provided by the large prospective
study of van Rij et al.,35 who followed 145 limbs with 850
IPVs, which were directly ligated under duplex ultrasound
guidance.35 To distinguish between residual IPVs and new
IPVs causing REVAS the limbs were topographically mapped
at initial treatment for subsequent serial postoperative
duplex examinations. At 3 years, they observed that 76% of
limbs had developed 380 further IPVs. Of these, 152 (40%)
recurred at the site of the IPV ligation owing to neo-
vascularization (same site REVAS), and, most importantly,
225 (59%) previously normal perforators by duplex exami-
nation increased their diameter and became incompetent
over the follow-up period (new REVAS), which is indicative
of disease progression. The sole series of direct thermal
ablation of IPVs with long-term data comes from the debate
opponent’s unit.36 The authors described the results of an
audit in terms of 82 of the 106 initially treated patients (25
were excluded owing to distance). Sixty-seven patients
responded, of whom 37 agreed to participate (35% of the
original cohort and 55% of the respondents). Of the 125
IPVs originally treated 81% were closed (21% open) in 20
limbs (34% of limbs), while 24% of the limbs demonstrated
new IPVs. Kiguchi et al. treated 62 C6 patients with
repeated sclerotherapy under duplex guidance and found
54% occluded at a mean of 30.2 months.37 Finally, the case
series of Masuda et al. illustrates the recurrence of
incompetence in IPVs following ultrasound-guided liquid
sclerotherapy of IPVs in 80 limbs (70% C2e4).38 Although
98% of the IPVs were occluded initially on duplex ultra-
sound, at 1.5 years only, 75% remain occluded.OVER TIME RECURRENCE IS RELATED TO PROGRESSION OF
CHRONIC VENOUS INSUFFICIENCY
Disease progression has been deﬁned as a result of the
natural history and evolution of the disease, where the
involved varicosities are not dilated and varicose at the time
of the initial treatment, but develop reﬂux owing to the
“natural history of the disease process”.39 van Rij et al.
followed 92 patients with 127 limbs that underwent L&S of
the GSV with concomitant duplex ultrasound-guided direct
ligation of signiﬁcant IPVs.39 These patients underwent se-
rial duplex and air plethysmography studies. At 3 months,
13.7% had clinical evidence of recurrence, and this ﬁgure
jumped to 51.7% at 3 years. Over the follow-up period,
there was a progressive increase in the venous ﬁlling index,
a measure of reﬂux, in a great proportion of limbs. This
indicated a physiologic recurrence that paralleled and pre-
ceded clinical recurrence. Despite ligation of all signiﬁcant
IPVs at initial surgery, new IPVs rose to 59% and 90% of
limbs at 2 and 3 years, respectively, which is indicative of
the major role of disease progression in REVAS. The previ-
ously quoted REVATA study of Bush et al. found that that atotal of 40% of all REVAS was due to disease progression in
new sitesd16% at the SSV and 24% at the anterior acces-
sory GSV, which were all previously normal.8
One can only conclude that pre-emptive treatment of
perforator incompetence at the time of GSV surgery is not
associated with prevention of recurrence. The best strategy
for treatment of recurrent varicose veins after GSV ablation
and removal of varicosities may be similar to that employed
for arterial occlusive disease or dental carries with periodic
check-ups and treatment as the problem arises.REFERENCES
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